CatSci Ltd.

https://www.catsci.com

LinkedIn: https://www.linkedin.com/company/catsci-ltd

CatSci Ltd was formed in December 2010, after the founders saw an opportunity in the market for a unique catalyst screening company. CatSci was consequently spun out of AstraZeneca’s Catalyst Screening Facility, replicating the same high laboratory standards and experimental workflows. We soon enhanced our offering to provide end-to-end, perfect-for-purpose process research and development services for emerging, mid-sized and large pharma organisations worldwide. CatSci has since developed into the fully integrated innovation partner for medicines development that it is today. Our fully integrated chemical development, material science, preformulation, GMP analytical, HPAPIs and new modalities teams leverage their extensive knowledge across the CMC landscape and refined workflows based on world-leading approaches that have evolved over years of experience with large pharma. This allows us to deliver complex projects on time and to the requisite quality. In 2020, we created a network of trusted partners across the pharmaceutical supply chain to add strategic value to our customers’ projects throughout the journey from molecule to medicine. In 2021, we opened our second facility in Dagenham, a Centre of Excellence for GMP analytical science that includes small molecules, TACS, glues, oligonucleotides and other complex synthetic medicines. In 2022, we received investment from Keensight Capital to support the expansion of our workforce, laboratories and offering so that we can continuously offer more and better to our customers. We opened our SafeBridge®-certified HPAPI laboratory to address High Potency API development project demands. In 2023, we partnered with AGC Pharma Chemicals Europe, a global CDMO with a proven track record, to offer our customers scalable small molecule API manufacturing from grams to tonnes. In 2023, we also opened our dedicated oligonucleotides laboratory to expedite and de-risk the development and manufacture of RNA therapies. In 2024, CatSci acquired Reach Separations to offer expert end-to-end chromatographic support from discovery to manufacture. *

	Start	2010-12-01 established (s-off)
	Group	CatSci (Group)
	Predecessor	AstraZeneca (Group)
	Industry	drug development services
	Industry 2	analytical services

	Street	CBTC2 Capital Business Park
	City	CF3 2PX Wentloog, Cardiff
	Tel	+44-33-0025-0170
		Address record changed: 2024-07-02

Basic data	Employees	n. a.

		�About Section� taken from web site of organisation on 01.07.

		Record changed: 2024-07-02

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Associations

Advertise

CatSci Ltd.

More documents for CatSci (Group)